

09-06-00

DAC \$

Express Mail Label No.: EJ770260491US
Date of Deposit: September 5, 2000

Attorney Docket No. 00960-515 (CBM-15)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Sampath *et al.*

RECEIVED

SEP 12 2000

ASSIGNEE: CREATIVE BIOMOLECULES, INC.

SERIAL NO.: 08/851,628

EXAMINER: D.S. Romeo OFFICE OF PETITIONS

FILING DATE: May 6, 1997

ART UNIT: 1646

FOR: NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

September 5, 2000
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:



Petition to Correct Inventorship Under 37 C.F.R. §1.48 (1 page);
Statement of Added Inventor, Slobodon Vukicevic (1 page);
Consent of Assignee to Change of Inventorship (1 page);
Combined Declaration and Power of Attorney for Patent Application (3 pages); and
One check (#6627) in the amount of \$130.00 as payment of petition fee; and
Return Postcard.

No additional fee is believed to be due. However, the Commissioner is authorized to charge any additional fees due to Deposit Account No. 50-0311 (Ref. No. 00960-515, CBM-15). A duplicate copy of this transmittal letter is enclosed.


Respectfully submitted,



Ivor R. Elmfi, Reg. No. 39,529
Michel Morency, Limited Recognition
Shelby J. Walker, Reg. No. 45,192
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No.: EJ770260491US
Date of Deposit: September 5, 2000

Attorney Docket No.: 00960-515 (CBM-15)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Sampath *et al.*
ASSIGNEE: CREATIVE BIOMOLECULES, INC.
SERIAL NO.: 08/851,628 EXAMINER: D.S. Romeo
FILING DATE: May 6, 1997 ART UNIT: 1646
FOR: NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

RECEIVED

SEP 12 2000


Assistant Commissioner for Patents
Washington, D.C. 20231

OFFICE OF PETITIONS

STATEMENT OF ADDED INVENTOR, SLOBODON VUKICEVIC

This is a statement under 37 C.F.R. § 1.48(a) from the undersigned, Slobodon Vukicevic, who is to be added as an inventor to the above-identified patent application. The error of failing to include me, Slobodon Vukicevic, as an inventor occurred without any deceptive intention on my part.

Respectfully submitted,



Slobodon Vukicevic

Date: 7/24/00

TRADOC:1325028.1(S##C01!.DOC)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Sampath *et al.*
ASSIGNEE: CREATIVE BIOMOLECULES, INC.
SERIAL NO: 08/851,628 EXAMINER: D.S. Romeo
FILING DATE: May 6, 1997 ART UNIT: 1646
FOR: NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
SEP 12 2000

OFFICE OF PETITIONS

CONSENT OF ASSIGNEE TO CHANGE OF INVENTORSHIP

CREATIVE BIOMOLECULES, INC., a corporation and owner of the above-identified patent application, Serial No. 08/851,628, filed May 6, 1997, assignment recorded on November 28, 1997, at Reel 8827/Frame 0589, hereby consents to the addition of Slobodon Vukicevic as an inventor of the above-identified application. 37 C.F.R. §1.48(a)(4).

CREATIVE BIOMOLECULES, INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent application identified above by virtue of assignment of the patent application identified above.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent application identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,


Cheryl Lawton
Vice President, General Counsel
CREATIVE BIOMOLECULES, INC.

Date: July 24, 2000